Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriers

A new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While offering potential benefits, experts highlight concerns about its high cost and the need for early diagnosis. The drug's real-world impact in India remains a subject of discussion among neurologists and the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mp3YCOg
via IFTTT